Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

By Chen Jianping   Smith Melissa   Kolinsky Kenneth   Adames Violeta   Mehta Nila   Fritzky Luke   Rashed Mohammad   Wheeldon Eric   Linn Michael   Higgins Brian  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 651-659

Springer Publishing Company

Access to resources Recommend Favorite

In vitro modeling of HER2-targeting therapy in disseminated prostate cancer

By          

International Journal of Oncology, Vol. 45, Iss. 5, 2014-01 ,pp. : 2153-2158

Spandidos Publications

Access to resources Recommend Favorite

Pancreatic Cancer Epidermal Growth Factor Receptor ( EGFR ) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response

By Tzeng Ching-Wei   Frolov Andrey   Frolova Natalya   Jhala Nirag   Howard J.   Vickers Selwyn   Buchsbaum Donald   Heslin Martin   Arnoletti J.  

Annals of Surgical Oncology, Vol. 14, Iss. 7, 2007-07 ,pp. : 2150-2158

Springer Publishing Company

Access to resources Recommend Favorite

Targeting the ATR-CHK1 Axis in Cancer Therapy

By Rundle Stuart   Bradbury Alice   Drew Yvette   Curtin Nicola J.  

Cancers, Vol. 9, Iss. 5, 2017-04 ,pp. : 41-41

MDPI

Access to resources Recommend Favorite

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition

By Mizukami Takuro   Togashi Yosuke   Sogabe Shunsuke   Banno Eri   Terashima Masato   De Velasco Marco A   Sakai Kazuko   Fujita Yoshihiko   Tomida Shuta   Nakajima Takako Eguchi   Boku Narikazu   Nishio Kazuto  

International Journal of Oncology, Vol. 47, Iss. 2, 2015-08 ,pp. : 499-505

Spandidos Publications

Access to resources Recommend Favorite